Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Key Inclusion Criteria:

• ≥ 18 years old

• Body mass index (BMI) of ≥ 18 kg/m2

• Evidence of bronchiectasis per CT

• Evidence of chronic pulmonary Pseudomonas aeruginosa infection

• Willing to undergo sputum induction procedures at designated study visits, andwilling to provide expectorated sputum samples at all other timepoints (for subjectswho are able to expectorate)

• FEV1 ≥ 35% of predicted normal [per Global Lung Function Initiative (GLI) standards]at Screening

• For Cohort A: have not received chronic inhaled antipseudomonal antibiotics regimenfor at least 3 months prior to Visit 1

• For Cohort B: have received chronic inhaled antipseudomonal antibiotics regimen forat least 3 months prior to Visit 1

Key Exclusion Criteria:

• Abnormal vital signs at Screening

• History of lung transplantation

• History of cystic fibrosis

• History of α1-antitrypsin deficiency

• History of primary or acquired immunodeficiency syndromes

• History of COPD

• History of pulmonary malignancy or any other malignancy requiring treatment

• History of prolonged QT syndrome

• History of hemoptysis

• Recent significant weight loss

• Recent use of supplemental oxygen during the day while at rest

• Recent use of cigarettes, cigars, or pipes, or used tobacco or other nicotine sourceby vaping

• Recent changes in either the treatment regimen or initiation of treatment with: oralmacrolides, hypertonic saline, mucolytics, bronchodilator medications, or oralcorticosteroids

• Currently receiving treatment for active infection at any site

• Female pregnant of breastfeeding